

South Carolina
Department of Health and Human Services
Post Office Box 8206
Columbia, South Carolina 29202-8206

Pharmacy and Therapeutics (P&T) Committee Meeting
November 4, 2015
MINUTES

1. Call to Order

A meeting of the P&T Committee convened at 4:00 p.m. on Wednesday, November 4, 2015.

2. Welcome

Edward Behling, MD, called the meeting to order and welcomed members, guests, and staff members.

Dr. Behling opened the meeting by stating that the P&T Committee meetings are held in compliance with the Freedom of Information Act's (FOIA) mandate that the public is notified when the public's business is being done, and that furthermore, the public has been notified that this facility is accessible to individuals with disabilities, and special accommodations could have been provided if requested in advance.

3. Committee Members Present:

Joni Bollinger, MD
James Lindsey, MD
Divya Ahuja, MD

Tan Platt, MD
Edward Behling, MD
Gregory Browning, MD

Thomas Phillips, R.Ph.
Cheryl Hartvigsen, R.Ph.
Phillip Mubarak, MD

SC DHHS Staff:

Bryan Amick, PharmD, MBA
Jim Bradford, MD
Damian Bridges, MHA
Constance Holloway, JD
Janet Giles

Magellan Medicaid Admin:

Lisa Correll, PharmD
Lori Ash

4. Discussion Topics

A. Committee Meeting Minutes, Wednesday, August 5, 2015

The draft minutes from the previous P&T Committee meeting were emailed to the members so that they could review the document prior to the meeting. The minutes were approved unanimously.

B. Public Comment

Company	Speaker	Drug/Class
Otsuka American Pharm	Michael DeLucia, R.Ph.	Antipsychotics, Inj.
Janssen	Megan Jones, PharmD	Antipsychotics, Inj.
Purdue Pharma, LP	Maribeth Kowalski, PharmD	Opioids, Long Acting
Pfizer, Inc.	Barbara Phillips, PharmD	Opioids, Long Acting
Abbvie	Olivia Lee, PharmD	Hepatitis C
Bristol-Myers Squibb	Manan Shah, PharmD	Hepatitis C

C. Drug Classes for Review

Lisa Correll led the discussion for the following drug classes:

Classes for Re-Review

- Antipsychotics, Injectables
- Opioids Long Acting
- Ophthalmics, Antihistamines
- Hepatitis C

The chart below represents the recommendations from the P & T Committee:

ANTIPSYCHOTICS, INJECTABLES	
Preferred	Non-Preferred
Invega® Sustenna® Invega Trinza™ Risperdal® Consta®	Abilify Maintena® Zyprexa Relprevv

OPIOIDS, LONG ACTING	
Preferred	Non-Preferred
Embeda® Fentanyl Patch Morphine Sulfate SA	Butrans® Duragesic® Exalgo® Hysingla® ER Kadian® MS Contin® Opana® OxyContin® Zohydro® ER

OPHTHALMICS, ANTIHISTAMINES	
Preferred	Non-Preferred
Alaway®	Azelastine
Pataday®	Bepreve™
Pazeo®	Elestat®
Lastacaft®	Emadine®
Zaditor®	Patanol®

Hepatitis C	
Preferred	Non-Preferred
Daklinza™	Harvoni®
Technivie™	Olysio®
Viekira Pak™	Sovaldi®

5. **Old Business**

None

6. **New Business**

Dr. Tan Platt gave a tribute to Dr. Sharm Steadman. Lisa Correll presented new drugs to market and classes for re-review.

7. **Resolved Items**

Recommendations regarding PDL status for drugs in the following classes were approved for submission to DHHS.

Classes for Re-Review

Antipsychotics, Injectables
Opioids Long Acting
Ophthalmics, Antihistamines
Hepatitis C

8. **Closing Comments**

The next meeting will be held on Wednesday, February 3, 2016, at 4:00 p.m.

9. **Adjournment**

The meeting adjourned at 5:48 p.m.